COSCIENS Biopharma (CSCI) Competitors $3.77 -0.08 (-2.08%) Closing price 08/6/2025 03:59 PM EasternExtended Trading$3.74 -0.02 (-0.66%) As of 08/6/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesSEC FilingsTrendsBuy This Stock CSCI vs. SNTI, GANX, PRLD, EGRX, ELYM, PEPG, JSPR, RNXT, XCUR, and NBRVShould you be buying COSCIENS Biopharma stock or one of its competitors? The main competitors of COSCIENS Biopharma include Senti Biosciences (SNTI), Gain Therapeutics (GANX), Prelude Therapeutics (PRLD), Eagle Pharmaceuticals (EGRX), Eliem Therapeutics (ELYM), PepGen (PEPG), Jasper Therapeutics (JSPR), RenovoRx (RNXT), Exicure (XCUR), and Nabriva Therapeutics (NBRV). These companies are all part of the "pharmaceutical products" industry. COSCIENS Biopharma vs. Its Competitors Senti Biosciences Gain Therapeutics Prelude Therapeutics Eagle Pharmaceuticals Eliem Therapeutics PepGen Jasper Therapeutics RenovoRx Exicure Nabriva Therapeutics COSCIENS Biopharma (NASDAQ:CSCI) and Senti Biosciences (NASDAQ:SNTI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership. Which has more risk and volatility, CSCI or SNTI? COSCIENS Biopharma has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500. Comparatively, Senti Biosciences has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500. Is CSCI or SNTI more profitable? Senti Biosciences has a net margin of 0.00% compared to COSCIENS Biopharma's net margin of -194.50%. COSCIENS Biopharma's return on equity of -101.01% beat Senti Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets COSCIENS Biopharma-194.50% -101.01% -43.90% Senti Biosciences N/A -177.24%-67.38% Do insiders & institutionals hold more shares of CSCI or SNTI? 0.7% of COSCIENS Biopharma shares are held by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are held by institutional investors. 0.1% of COSCIENS Biopharma shares are held by insiders. Comparatively, 3.1% of Senti Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media refer more to CSCI or SNTI? In the previous week, Senti Biosciences had 1 more articles in the media than COSCIENS Biopharma. MarketBeat recorded 1 mentions for Senti Biosciences and 0 mentions for COSCIENS Biopharma. COSCIENS Biopharma's average media sentiment score of 0.00 equaled Senti Biosciences'average media sentiment score. Company Overall Sentiment COSCIENS Biopharma Neutral Senti Biosciences Neutral Which has higher earnings and valuation, CSCI or SNTI? COSCIENS Biopharma has higher revenue and earnings than Senti Biosciences. COSCIENS Biopharma is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCOSCIENS Biopharma$9.59M1.24-$15.31M-$5.80-0.65Senti Biosciences$2.56M17.22-$52.79M-$10.84-0.16 Do analysts prefer CSCI or SNTI? Senti Biosciences has a consensus target price of $8.50, suggesting a potential upside of 402.96%. Given Senti Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Senti Biosciences is more favorable than COSCIENS Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score COSCIENS Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Senti Biosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummarySenti Biosciences beats COSCIENS Biopharma on 10 of the 15 factors compared between the two stocks. Get COSCIENS Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CSCI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CSCI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CSCI vs. The Competition Export to ExcelMetricCOSCIENS BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.11M$3.01B$5.57B$9.47BDividend YieldN/A2.41%4.31%4.13%P/E Ratio-0.6516.5729.3723.99Price / Sales1.24314.98444.2496.60Price / CashN/A42.1735.8458.51Price / Book1.087.818.085.58Net Income-$15.31M-$54.52M$3.26B$265.35M7 Day Performance-3.58%0.41%0.46%-0.07%1 Month Performance9.59%9.93%4.84%1.76%1 Year PerformanceN/A15.18%30.29%25.39% COSCIENS Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CSCICOSCIENS BiopharmaN/A$3.77-2.1%N/AN/A$12.11M$9.59M-0.6520Upcoming EarningsSNTISenti Biosciences1.7661 of 5 stars$1.80-3.7%$8.50+372.2%+1.2%$48.77MN/A-0.174News CoverageUpcoming EarningsGANXGain Therapeutics2.3109 of 5 stars$1.57-3.1%$8.20+422.3%+54.5%$48.71M$50K-1.8320News CoveragePRLDPrelude Therapeutics3.2971 of 5 stars$0.83-2.4%$4.50+441.1%-84.8%$48.11M$7M-0.49120Positive NewsUpcoming EarningsGap UpHigh Trading VolumeEGRXEagle Pharmaceuticals1.9882 of 5 stars$3.69flatN/A-29.6%$47.92M$257.55M0.00100Gap DownELYMEliem TherapeuticsN/A$1.60+10.3%N/A-76.3%$47.60MN/A-3.029Gap UpPEPGPepGen2.6667 of 5 stars$1.38-3.5%$7.67+455.6%-85.4%$46.79MN/A-0.4430Upcoming EarningsJSPRJasper Therapeutics2.5625 of 5 stars$2.95-4.8%$29.75+908.5%-82.6%$46.57MN/A-0.5620Upcoming EarningsRNXTRenovoRx2.4974 of 5 stars$1.22-2.4%$7.25+494.3%+5.3%$45.72M$40K-3.056News CoverageUpcoming EarningsXCURExicure0.892 of 5 stars$6.63-8.2%N/A+1,108.2%$45.61M$500K-1.7450Upcoming EarningsNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070 Related Companies and Tools Related Companies SNTI Competitors GANX Competitors PRLD Competitors EGRX Competitors ELYM Competitors PEPG Competitors JSPR Competitors RNXT Competitors XCUR Competitors NBRV Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CSCI) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding COSCIENS Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share COSCIENS Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
